This article is more than 5 years old. Information may no longer be current.
HR loss predicted lymph node metastasis, poor prognosis in endometrial cancer
Click Here to Manage Email Alerts
Patients with ER-negative and PR-negative endometrial cancer were more likely to develop lymph node metastasis and experience poor disease-specific survival, according to study results.
The analysis — a substudy of the Molecular Markers in Treatment of Endometrial Cancer trial — allowed researchers to assess hormone receptor (HR) and p53 status as potential biomarkers in 832 patients with endometrial carcinoma.
Overall, 18% of patients had ER-negative/PR-negative endometrial cancer, and 24% of patients overexpressed p53.
Researchers found that double-negative HR status and p53 expression were associated with nodal metastases, high Federation International of Gynecology and Obstetrics stage, non-endometrioid histology, high grade and poor prognosis (P<.001 for all).
After adjustments for pre-operative curettage histology, ER and PR loss were significantly associated with lymph node metastasis (OR=2.0; 95% CI, 1.1-3.7).
After adjustments for age, stage, histologic type, grade and myometrial infiltration, results indicated that double-negative HR status also predicted poor disease-specific survival (HR=2.3; 95% CI, 1.4-3.9).
In patients with lymph node-negative endometrioid tumors, the association between double-negative HR status and poor disease-specific survival was evident regardless of adjustments for tumor grade.
“Implementing hormone receptor status to improve risk stratification for selecting patients unlikely to benefit from lymphadenectomy seems justified,” the researchers concluded.
Disclosure: See the study for a full list of the researchers’ relevant financial disclosures.
Click Here to Manage Email Alerts